Regencor
Regencor is a pioneering regenerative medicine company focused on developing therapies for cardiovascular disease, especially post-myocardial infarction. Their mission is to transform patient lives by promoting cardiac regeneration using proprietary biologics like REG101, which stimulates heart tissue repair and reduces scar formation. The company aims to bring innovative, non-invasive treatments to market that can restore heart function and prevent heart failure.
Industries
Nr. of Employees
small (1-50)
Regencor
Patents
Products
Recombinant FSTL1-based cardiac regenerative protein therapeutic
A non-glycosylated recombinant human protein therapeutic designed to stimulate cardiomyocyte proliferation and new vessel formation within the infarct zone, reduce scar volume, and restore cardiac function after myocardial infarction; developed for outpatient subcutaneous administration.
Recombinant FSTL1-based cardiac regenerative protein therapeutic
A non-glycosylated recombinant human protein therapeutic designed to stimulate cardiomyocyte proliferation and new vessel formation within the infarct zone, reduce scar volume, and restore cardiac function after myocardial infarction; developed for outpatient subcutaneous administration.
Services
Planning and execution of preclinical safety and efficacy studies intended to support regulatory IND submissions.
Conduct of efficacy studies demonstrating myocardial regeneration, scar reduction and functional recovery after myocardial infarction in rodents and pigs.
Development and evaluation of continuous subcutaneous infusion delivery regimens and compatibility testing with wearable injectors for outpatient administration.
Planning and execution of preclinical safety and efficacy studies intended to support regulatory IND submissions.
Conduct of efficacy studies demonstrating myocardial regeneration, scar reduction and functional recovery after myocardial infarction in rodents and pigs.
Development and evaluation of continuous subcutaneous infusion delivery regimens and compatibility testing with wearable injectors for outpatient administration.
Expertise Areas
- Cardiac regenerative therapeutics
- Preclinical large-animal and rodent efficacy studies
- Protein biologics discovery and engineering
- Subcutaneous continuous-infusion drug delivery
Key Technologies
- Recombinant protein expression and purification
- Non-glycosylated protein variant engineering
- Whole-proteome screening platform
- Preclinical porcine and rodent MI models
News & Updates
On March 20, 2023, Regencor announced the appointment of Philip Janiak, Ph.D., and Ken Mahaffey, M.D., to its Scientific Advisory Board, joining Nabil Dib, M.D.
On May 18, 2022, Regencor announced the appointment of Sean Edwards as President and CEO, with Tom Okarma remaining as Executive Chairman.
On November 24, 2021, Regencor received a $3.9 million award from CIRM to perform IND-enabling studies of their regenerative protein FSTL1.
On September 17, 2015, a protein capable of regenerating heart cells after a heart attack was discovered.
A protein capable of regenerating heart cells after a heart attack was discovered, as reported on September 17, 2015.
A report on September 27, 2015, about FSTL1 promoting heart regeneration.
On March 20, 2023, Regencor announced the appointment of Philip Janiak, Ph.D., and Ken Mahaffey, M.D., to its Scientific Advisory Board, joining Nabil Dib, M.D.
On May 18, 2022, Regencor announced the appointment of Sean Edwards as President and CEO, with Tom Okarma remaining as Executive Chairman.
On November 24, 2021, Regencor received a $3.9 million award from CIRM to perform IND-enabling studies of their regenerative protein FSTL1.
On September 17, 2015, a protein capable of regenerating heart cells after a heart attack was discovered.
A protein capable of regenerating heart cells after a heart attack was discovered, as reported on September 17, 2015.
A report on September 27, 2015, about FSTL1 promoting heart regeneration.